GI Hepatobiliary

Hepatocellular Carcinoma

Localized

No Prior Therapy

Prior Therapy

1st Line

2nd line

No Trials Currently Available

Cholangiocarcinoma

1st Line

1st or 2nd Line

2nd Line or more

No Trials Currently Available

CROSS-DISEASE TRIALS:

IRB #20929
Phase II study of TSR-022 (COBOLIMAB) in combination with TSR-042 (DOSTARLIMAB) for the treatment of advanced hepatocellular carcinoma

IRB # 20744
Pembrolizumab + Lenvatinib + TACE (Transarterial Chemoembolization) vs Placebo + TACE in Intermediate Stage HCC

IRB #23365
A Phase II Study to Evaluate the Efficacy and Safety of Y-90, Atezolizumab and Cabozantinib Among Patients with unresectable and locally-advanced HCC

IRB # 20357
[NCI CIRB] A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers

IRB# 16033
Phase II study of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of Fluorouridine and Dexamethasone given concurrently with systemic mFOLFRIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma

KEY
- Open to Enrollment
- In Development
- Enrollment on Hold

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
IRB# 23005
EA2197, Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial